SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launch
SK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market. Biohaven is currently evaluating the daily oral therapy, called opakalim or BHV-7000, in a phase 2/3 study … Continued